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Abstract
Background: Lymph node involvement could help to predict the prognosis of pathological T1 (pT1, diameters of
≤3 cm) non-small cell lung cancer (NSCLC). This study assessed the clinicopathological factors and associated lymph
node involvement in invasive lung adenocarcinoma (IAC) and squamous cell lung cancer (SCC) and the overall and
disease-free survival associated with these factors.
Methods: Three hundred and twenty-five patients with pathological T1 NSCLC (253 IAC and 72 SCC) were retrospectively
analyzed from a pool of 1094 primary lung cancer patients. The data were assessed using multiple logistic regression,
Kaplan-Meier curves and multivariable analyses.
Results: Among patients with a ≤30-mm tumor lesion (N = 325), N1 and N2 lymph node involvement was found in 28
(8.6%) and 34 (10.4%) patients, respectively. Lymph node metastasis occurred in 13.0% (33/253) of pT1 IAC patients and
40.3% (29/72) of SCC patients. Carcinoembryonic antigen (CEA) levels, SCC by histology, and tumor lesions larger than
1.0 cm were associated with lymph node involvement (P < 0.0001, <0.0001, and 0.048, respectively). In IAC patients,
negative lymph nodes were associated with better overall survival compared with lymph node-positive ones (P = 0.
021). No significant difference was observed in SCC patients regardless of lymph node status (P = 0.40). Multivariable
Cox analysis revealed that lymph node involvement was an independent prognostic predictor of overall IAC patient
survival (P = 0.041), but not of SCC patient survival (P = 0.470). Chemotherapy was administered to 72.2% (52/72) of SCC
patients, a significantly higher rate when compared with that of IAC patients (42.3%, 107/253).
Conclusions: Lymph node metastasis was inversely associated with the overall survival of IAP patients, but not with the
survival of SCC patients. Patients with pT1 SCC exhibited a significantly higher rate of lymph node involvement when
compared with IAC patients. Thus, a systematic lymph node dissection should be performed in pT1 IAC patients, especially
in patients with IAC larger than 1.0 cm, for additional treatment selections to improve survival.
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Background
Lung cancer is one of the leading causes of cancer-
related mortality in the world [1, 2]. Cancer metastasis
(e.g., lymph node metastasis or distant metastasis to
other organs) significantly contributes to lung cancer
patient death [3, 4]. Non-small cell lung cancer (NSCLC)
accounts for up to 85% of all lung cancer cases. The vast
majority of diagnosed NSCLCs are adenocarcinomas
(ADCs) or squamous cell carcinomas (SCCs), and the
incidence of lung ADC has increased rapidly, becoming
the most common histological subtype [5, 6].
The effect of clinicopathological characteristics on lung
cancer lymph node metastasis in patients with pathological
T1 (pT1) NSCLC remains the subject of debate, including
histological subtype, tumor localization, and pleural and vas-
cular invasion. Several previous studies reported that lung
adenocarcinoma in situ (AIS) and minimally invasive adeno-
carcinoma (MIA) exhibited 100% 5-year disease-free sur-
vival (DFS) after lung resection [7, 8]. In contrast, invasive
adenocarcinoma (IAC) contributes significantly to lymph
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node metastasis [9]. Thus, the data on lymph node metasta-
sis from IAC should be evaluated regardless of AIS and
MIA. Previous studies [10, 11] demonstrated that there was
no difference in lymph node metastasis between SCC and
lung adenocarcinoma, but not IAC in pT1 NSCLC. There-
fore, the difference of lymph node metastasis from IAC and
SCC should be fully evaluated with a tumor size less than
30 mm (stage T1). Yasuhiro et al. [12] reported that clinico-
pathological factors, such as tumor size, maximum stan-
dardized uptake value (SUV), and serum tumor markers,
may not predict lymph node metastasis in patients with lung
pT1 SCC [10]. Nevertheless, others have indicated that clini-
copathological factors can be useful aids to predict the
lymph node metastasis and the lymph node involvement-
related prognosis in early stage NSCLC patients [11, 13].
Thus, further study is needed to assess and evaluate whether
other clinicopathological characteristics could be useful pre-
dictors for lung cancer lymph node metastasis and to deter-
mine whether lymph node involvement is associated with
survival of such lung cancer patients.
Thus, in this study, we identified and assessed clinicopath-
ological factors potentially associated with lymph node me-
tastasis. Furthermore, we characterized the prognosis of pT1
IAC and SCC patients with lymph node involvement.
Methods
Study population
In this study, we retrospectively reviewed and analyzed
1094 primary lung cancer cases that had been treated via
surgical resection at Zhoushan Hospital (Zhejiang, China)
between January 2007 and December 2014. All patients
received routine or contrast-enhanced chest computed
tomography (CT) scans (Sensation 16, Siemens, Erlangen,
Germany) prior to surgery. Preoperative cardiopulmonary
tests, abdominal CT or abdominal ultrasonography im-
aging, brain magnetic resonance or brain CT imaging, and
bone scanning were also performed on all patients. After
surgery, NSCLC diagnosis was confirmed histologically in
accordance with the World Health Organization classifica-
tion system by two pathologists. Lung adenocarcinoma was
classified using the new TNM-7 version IASLC/ATS/ERS
staging system [6]. All patients received systematic hilar
and mediastinal lymphadenectomies according to the 2011
National Comprehensive Cancer Network (NCCN) guide-
lines. Lymph node N stages were determined by reviewing
intraoperative frozen sections and post-surgical tissue
sections of resected lymph node tissues collected during
lobectomy or limited resection (segment or wedge). No pa-
tients received preoperative chemotherapy, radiotherapy, or
chemoradiotherapy.
We also collected relevant clinicopathological factors, in-
cluding age, gender, lymphatic and vascular vessel invasion,
bronchial invasion, preoperative serum carcinoembryonic
antigen (CEA) levels, and the performance of relevant
surgical procedures. CEA levels >5.0 IU/Ml were assessed
as positive, as defined by the assay kit (Beckman Coulter,
USA). Eighty-four patients were excluded from this study
due to the presence of multiple lung lesions or other exclu-
sion factors. Patients who met exclusion criteria included
(i) 17 patients with large cell lung cancer, 10 with adenos-
quamous carcinoma, 6 with pulmonary sarcomatoid
carcinoma, 6 with lymphoepithelioma-like carcinoma, 1
with lung pleomorphic carcinoma, and 15 with neuroendo-
crine tumors, (ii) 305 NSCLC patients with pathological
T2–T4 stage diseases, and (iii) 325 patients with a subtype
of AAH, AIS, or MIA without any lymph node metastases
[7, 8]. The remaining 325 patients with pT1 (253 with IAC
and 72 with SCC) were included in this study. Among the
patients included in the study, there were 226 with IA
stage, 1 with IB stage, 24 with IIA stage, 1 with IIB stage,
and 33 with IIIA stage. This study was approved by the
Ethics Committee of Zhoushan Hospital of Wenzhou
Medical University (Zhoushan, Zhejiang, China). All par-
ticipants, or their next kin, provided written informed
consent before study enrollment.
Adjuvant chemotherapy
Platinum-based adjuvant chemotherapy was given to 157
patients with risk factors (such as lymph node metastasis,
pleural invasion, and poor tumor differentiation) for 4 to
6 weeks after surgery. No mortality occurred in these 157
patients after adjuvant chemotherapy.
Follow-up
Follow-up examinations were conducted for all patients,
and the follow-up visit occurred in our outpatient clinic at
3-month intervals for the first year and 6-month intervals
thereafter. CT scans and serum CEA levels were used to as-
sess tumor recurrence. Follow-up duration ranged from 2 to
102 months, with a mean of 36 months. The last follow-up
visit occurred in the month of June in 2015. The study end-
point was patient death, or the final follow-up visit. Overall
survival was defined as the time from surgery to death, or to
the final follow-up visit. The length of survival was defined
as the number of months from the date of surgical resection
to the date of patient death, or the final follow-up visit.
Statistical analysis
All statistical analyses were performed using the Statistical
Package for Social Sciences software, version 17.0 (SPSS,
Inc., Chicago, IL, USA). Pearson’s chi-squared test or Fisher’s
exact test was used to estimate the statistical significance be-
tween the categorized groups. The Kaplan-Meier curves
were used to assess patient survival. Multivariable analyses
of prognostic factors were performed using Cox’s propor-
tional hazard regression model. All factors with univariate
significance P values less than 0.05 were entered into a mul-
tivariable Cox model to estimate overall survival and lung
Zhang et al. World Journal of Surgical Oncology  (2017) 15:64 Page 2 of 8
cancer-specific survival. All statistical tests were two-sided
and P value ≤ 0.05 was considered statistically significant.
Results
Patient characteristics
Three hundred and twenty-five eligible patients with
pathological T1 NSCLC were included in this study,
including 253 (77.8%) IAC and 72 (22.2%) SCC patients.
Clinicopathological characteristics are summarized in
Table 1. In brief, there were 187 males and 138 females
with mean age of 62 years (±9 years, range 33 to
83 years). Two hundred and eighty-eight patients
(88.6%) underwent lobectomy, and 37 patients (11.4%)
underwent limited resection of tumor lesions. Overall,
we collected 3456 lymph nodes from these 325 patients.
In 874 lymph nodes from 62 patients, 197 were identi-
fied to have tumor metastasis [197/874 (22.5%)]. Among
these 62 patients, 28 (8.6%) and 34 (10.8%) had N1 and
N2 lymph node involvement, respectively. The 34
patients with N2 lymph node involvement had both N1
and N2 positive lymph nodes in 19 (5.8%) and 15 (4.6%)
patients who exhibited nodal skip metastasis, respect-
ively (Table 1).
Among the 325 patients, 28 (8.6%) had primary
pathological tumor lesions measuring ≤1.0 cm, whereas
182 (56.0%) had tumor lesions between 1.0 and 2.0 cm
and 115 (35.4%) had tumor lesions between 2.0 and
3.0 cm. Patients with subcentimeter-sized tumor lesions
did not exhibit lymph node metastasis. Pathologically,
positive lymph nodes were present in 29 (15.9%) pa-
tients with tumor lesions between 1.0 and 2.0 cm and
33 (28.7%) of the patients with tumor lesions between
2.0 and 3.0 cm. Lymph node involvement was observed
in 18.3% (33/180) of the non-smokers and 20.0% (29/
145) of the smokers. Lymph node metastasis occurred
in 13.0% (33/253) of pT1 IAC patients and 40.3% (29/
72) of SCC patients. Significant differences in lymph
node involvement (pN1, pN1+N2 or pN2) were
observed in pT1 patients when the patients were segre-
gated according to sex, preoperative CEA levels, patho-
logical tumor size, and histology (P = 0.020, <0.0001,
0.021 and <0.0001, respectively). However, no statistical
differences were observed when age, tumor location,
and surgical procedures were analyzed (P = 0.185,
0.150, and 0.720, respectively).
Additionally, differences were observed in IAC and
SCC patients with lymph node involvement and with a
tumor lesion smaller than 30 mm. In IAC patients, pre-
operational CEA levels and pathological tumor size were
associated with lymph node involvement (P < 0.0001 and
0.015, respectively). No association was observed be-
tween lymph node involvement and clinicopathological
data in small-sized SCC (Table 2).
Clinicopathological data: predicting lymph node
metastasis
We performed additional analysis of the association of
clinicopathological factors and lymph node involvement
using logistic multivariable analysis (Table 3). We found
that positive CEA levels, SCC, and tumor sizes larger
Table 1 Lymph node involvement and clinicopathological










Age (mean), yrs. 62 ± 9 61 ± 7 59 ± 9 58 ± 7
≤60 101 (31.1) 12 (3.7) 7 (2.2) 10 (3.1) 0.185
>60 162 (49.8) 16 (4.9) 12 (3.7) 5 (1.5)
Gender
Male 145 (44.6) 22 (6.8)a 14 (4.3) 6 (1.8) 0.020
Female 118 (36.3) 6 (1.8) 5 (1.5) 9 (2.8)
Tobacco smoking
history
Never 147 (45.2) 18 (5.5) 6 (1.8)b 9 (2.8) 0.044
Ever/current 116 (35.7) 10 (3.1) 13 (4.0) 6 (1.8)
CEA level
(n = 395)
<5.0 IU/mL 216 (66.5)c 16 (4.9) c 9 (2.8) 9 (2.8) <0.0001
≥5.0 IU/mL 47 (14.5) 12 (3.7) 10 (3.1) 6 (1.8)
Tumor location
Upper lobe 154 (47.4) 12 (3.7) 10 (3.1) 10 (3.1) 0.150
Middle lobe 18 (5.5) 2 (0.6) 1 (0.3) 2 (0.6)
Lower lobe 87 (26.8) 12 (3.7) 6 (1.8) 2 (0.6)
Middle-lower lobe 4 (1.2) 2 (0.6) 2 (0.6) 1 (0.3)
Type of surgery
Lobectomy 235 (72.3) 23 (7.1) 17 (5.2) 13 (4.0) 0.720
Limited resection 28 (8.6) 5 (1.5) 2 (0.6) 2 (0.6)
Adjuvant
chemotherapy
No 166 (51.1)d 0d 0d 0d <0.0001
Yes 97 (29.8) 28 (8.6) 19 (5.8) 15 (4.6)
Tumor size, cm
≤1.0 28 (8.6)e 0e 0 0 0.021
1.0–≤2.0 153 (47.1) 12 (3.7) 10 (3.1) 7 (2.2)
2.0–≤3.0 82 (25.2) 16 (4.9) 9 (2.8) 8 (2.5)
Histology
IAC 220 (67.7)f 12 (3.7)f 10 (3.1)f 11 (3.4)f <0.0001
SCC 43 (13.2) 16 (4.9) 9 (2.8) 4 (1.2)
CEA carcinoembryonic antigen, IAC invasive lung adenocarcinoma, SCC
squamous cell lung cancer
aMale vs. female
bnever smoked tobacco vs. ever/current
cCEA level <5.0 IU/mL vs. ≥5.0 IU/mL
dno adjuvant chemotherapy vs. adjuvant chemotherapy
etumor size ≤1.0 vs. 1.0–≤2.0 vs. 2.0–≤3.0
fIAC vs. SCC
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than 1.0 cm were significantly associated with lymph
node involvement (P < 0.0001, <0.0001, and 0.048, re-
spectively). Preoperational CEA levels and tumor size
were also associated with lymph node involvement in
253 IAC patients (P < 0.0001 and 0.023, respectively).
However, there was no significant association between
any of the clinicopathological characteristics and lymph
node involvement in SCC patients.
Lymph node involvement, clinicopathological
characteristics, and overall patient survival
Median overall survival was 84.8 months for pT1 patients
without lymph node involvement, which was significantly
longer than the median overall survival of patients with
lymph node involvement (66.9 months, P = 0.006, Fig. 1a).
When we examined the association between lymph node
involvement and the overall survival of patients with small-
sized IAC tumors or SCC, we found that IAC patients with
positive lymph nodes had a median overall survival of
64.1 months. This was a shorter median overall survival
when compared with patients without lymph node involve-
ment, a median overall survival of 85.1 months (P = 0.021,
Fig. 1b). In contrast, no significant difference was observed
in overall survival between patients with lymph node-
positive SCC and patients with lymph node-negative SCC
(67.1 vs. 75.8 months; P = 0.403, Fig. 1c). Additionally, mul-
tivariable analysis revealed that lymph node involvement
was an independent prognostic predictor of overall IAC
patient survival (P = 0.041, Table 4). However, no statisti-
cally significant association was observed between IAC
histologic types (lepidic, papillary, etc.) or CT images [pure
ground-glass opacity (GGO) vs. mixed GGO vs. solid nod-
ule] and the prognosis of IAC patients (P = 0.716, 0.366).
Additionally, no significant association was observed
Table 2 Lymph node involvement and clinicopathological characteristics of pT1 IAC and SCC patients, n (%)
Histology IAC P value SCC P value
pN0 (n = 220) pN (+) (n = 33) pN0 (n = 43) pN (+) (n = 29)
Age (mean), yrs.
≤60 90 (40.9) 17 (51.5) 0.263 11 (25.6) 12 (41.4) 0.201
>60 130 (59.1) 16 (48.5) 32 (74.4) 17 (58.6)
Gender
Male 104 (47.3) 15 (44.5) 0.854 41 (95.3) 27 (93.1) 1.00
Female 116 (52.7) 18 (54.5) 2 (4.7) 2 (6.9)
Tobacco smoking history
Never 139 (63.2) 20 (60.6) 0.847 8 (18.6) 5 (17.2) 1.00
Ever/current 81 (36.8) 13 (39.4) 35 (81.4) 24 (82.8)
CEA level (n = 395)
<5.0 IU/mL 183 (83.2) 14 (42.4) <0.0001 33 (76.7) 20 (69.0) 0.587
≥5.0 IU/mL 37 (16.8) 19 (57.6) 10 (23.3) 9 (31.0)
Tumor location
Upper lobe 131 (59.5) 18 (54.6) 0.145 23 (53.5) 14 (48.3) 0.760
Middle lobe 17 (7.7) 3 (9.1) 1 (2.3) 2 (6.9)
Lower lobe 72 (32.7) 11 (33.3) 15 (34.9) 9 (31.0)
Middle-lower lobe 0 1 (3.0) 4 (9.3) 4 (13.8)
Type of surgery
Lobectomy 197 (89.5) 27 (81.8) 0.236 38 (88.4) 26 (89.7) 0.591
Limited resection 23 (10.5) 6 (18.2) 5 (11.6) 3 (10.3)
Adjuvant chemotherapy
No 146 (66.4) 0 <0.0001 20 (46.5) 0 <0.0001
Yes 74 (33.6) 33 (100.0) 23 (53.5) 29 (100.0)
Tumor size, cm
≤1.0 27 (12.3) 0 0.015 1 (2.3) 0 1.00
1.0–≤2.0 136 (61.8) 18 (54.5) 17 (39.5) 11 (37.9)
2.0–≤3.0 57 (25.9) 15 (45.5) 25 (58.2) 18 (62.1)
CEA carcinoembryonic antigen, IAC invasive lung adenocarcinoma, SCC squamous cell lung cancer
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between surgery type (lobectomy vs. sublobectomy) and
the prognosis of IAC and SCC patients (P = 0.166). Add-
itionally, no improvement in the overall survival of patients
with a tumor less than 30 mm was observed in patients
given adjuvant chemotherapy (P = 0.730 and 0.710 in IAC
and SCC patients, respectively).
Gender (male vs. female, P = 0.028) was associated
with the overall survival of pT1 patients, but not with
IAC or SCC patients (P = 0.055 and 1.000, respectively).
Univariate analysis showed that preoperational CEA
levels were associated with the overall survival of IAC or
SCC patients (P = 0.010 and 0.021, respectively). How-
ever, multivariable analysis did not confirm this result in
IAC patients with tumors <30 mm (P = 0.120). Lymph
node metastasis was an independent survival factor for
patients with small-sized IAC (P = 0.041, Table 5).
Our data indicated no statistical difference in the sur-
vival of SCC patients with or without lymph node in-
volvement. We also analyzed the rate of postoperative
chemotherapy in patients with IAC or SCC and found
that patients with SCC underwent chemotherapy at a
rate of 72.2% (52/72), significantly higher than the rate
of 42.3% (107/253) in IAC patients.
Discussion
In this study, we retrospectively analyzed all primary
lung cancer patients who underwent treatment in our
hospital between January 2007 and December 2014.
Among these patients, we found no lymph node metas-
tases in pathological T1 AIS or MIA patients, which was
consistent with previous studies [7, 14]; therefore, we ex-
cluded these patients from our current study and chose
to investigate the IAC and SCC subtypes of NSCLC [15].
We found that the rate of lymph node involvement was
significantly higher in SCC patients when compared with
the lymph node involvement in IAC patients. Multiple
logistic regression analysis confirmed that SCC was sig-
nificantly associated with lymph node involvement; how-
ever, lymph node involvement was not an independent
prognosis factor for pT1 SCC patients. Lymph node-
positive IAC was associated with poor overall survival,
and lymph node involvement was an independent pre-
dictor of overall IAC survival. These results support the
notion that additional studies are needed to investigate
clinicopathological factors for association with lymph
node involvement and NSCLC metastasis.
Previous studies have reported no significant differ-
ences in lymph node involvement between IAC and
SCC, and that primary lung cancer histology predicted
occult mediastinal lymph node metastasis [10, 11]. How-
ever, a previous comparative study demonstrated that 12
of 25 of non-adenocarcinoma patients had lymph node
involvement [16], and this result is supported by our
current study showing that pT1 SCC patients had a
higher incidence of lymph node involvement when com-
pared with IAC patients. The variability in the results
reported by these different studies may be due to varia-
tions in study sample size, as well as the high incidence
Fig. 1 Kaplan-Meier curve analyses of overall survival of patients with pathological T1 IAC or SCC. Overall survival was stratified by lymph node
involvement (a), IAC lymph node involvement (b), or SCC lymph node involvement (c)
Table 3 Logistic multivariable analyses for the prediction of lymph
node-negative and lymph node-positive in pT1 IAC and SCC patients
Factors Odds ratio 95% Confidence interval P value





(<5.0 vs. ≥5.0 IU/mL)
3.647 1.908–6.971 <0.0001













CEA carcinoembryonic antigen, IAC invasive lung adenocarcinoma, SCC
squamous cell lung cancer
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of IAC patients. Our current study indicated that lymph
node involvement was an independent risk factor for
overall IAC patient survival, and this result is supported
by previous investigations [17, 18]. However, we did not
observe that lymph node metastasis was a predictor of
poor overall survival in SCC patients. This may be due
to the limited number of SCC patients with tumors
<30 mm. Furthermore, most SCC patients had a tumor
lesion >20 mm and lymph node metastasis; thus, post-
operative chemotherapy was given to most SCC
patients. Thus, the overall survival of these patients may
have been improved by this treatment. Another factor
improving patient survival might be the comparatively
lower malignancy of SCC relative to IAC, even though
these patients had lymph node metastasis.
The systematic dissection of lymph nodes during re-
section of subcentimeter lung cancer is a controversial
procedure. Several studies have reported subcentimeter
NSCLCs that were pathologically N1 or N2 [19, 20].
Others have reported no N1 or N2 lymph node involve-
ment in subcentimeter NSCLCs, suggesting that system-
atic lymph node dissection should be avoided in these
cases [11, 21]. In the current study, we found that there
was no lymph node metastasis in IAC or SCC patients
with tumor lesions less than 1 cm. We also observed
that IAC incidence was associated with tumor size. A
previous study reported that the incidence of lymph
node metastasis increased as tumor size increased [22].
In our study, tumor size was an independent predictor
for IAC lymph node metastasis. However, lymph node
involvement was independent of tumor size in SCC
patients. Tsutani et al. analyzed 100 patients with clinical
stage Ia SCC and reported that tumor size did not pre-
dict lymph node metastasis [12], and this result was sup-
ported by the results of our current study.
The current study observed that the incidence of lymph
node involvement was higher in male patients. Further-
more, Cox regression analysis indicated that male patients
had significantly poorer overall survival when compared
with their female counterparts. This result is consistent
with a previous study by Sakurai et al. [23]. Differences in
the incidence of lymph node metastasis between male and
female patients might be one reason for the different overall
survival time for small-sized lung cancer; thus, further
study is justified to validate this finding. Preoperative serum
CEA levels were associated with IAC lymph node metasta-
sis, but no clinical variables were associated with lymph
node involvement in SCC patients. These results are sup-
ported by a previous study by Bo et al. [9] that reported that
an abnormal CEA titer could predict the rate of lymph
node metastasis of T1a lung adenocarcinoma patients, but
not of SCC patients, which was reported by Tsutani et al.
[12]. Our current study demonstrated that certain clinico-
pathological factors could be used to predict metastasis of
pT1 lung cancer to the lymph nodes; however, the under-
lying mechanism of this metastasis remains un-
known. Our data indicate that pT1 metastasizes to
the lymph nodes even though it is an early stage
NSCLC. However, further confirmation of this result
is needed. Furthermore, our data showed no associ-
ation between IAC subtypes and CT imaging results
and the prognosis of IAC patients, which may be
due to the relatively short follow-up period or the
small sample size.
Table 4 Univariate and multivariable Cox analyses of overall IAC patient survival
Factors Univariate analysis Multivariable analysis
Hazard ratio 95% Confidence interval P value Hazard ratio 95% Confidence interval P value
Gender (male vs. female) 0.495 0.241–1.015 0.055
Preoperative CEA levels
(<5.0 vs. ≥5.0 IU/mL)
2.511 1.245–5.065 0.010 1.865 0.850–4.090 0.120
Lymph node metastasis
(absent vs. present)
2.360 1.114–5.001 0.025 2.154 1.033–4.493 0.041
CEA carcinoembryonic antigen, IAC invasive lung adenocarcinoma
Table 5 Univariate and multivariable Cox analyses of overall pT1 IAC and SCC patient survival
Factors Univariate analysis Multivariable analysis
Hazard ratio 95% Confidence interval P value Hazard ratio 95% Confidence interval P value
Gender (male vs. female) 0.493 0.263–0.926 0.028 0.525 0.279–0.988 0.046
Preoperative CEA levels
(<5.0 vs. ≥5.0 IU/mL)
2.777 1.599–4.824 <0.0001 2.455 1.395–4.321 0.002
Lymph node metastasis
(absent vs. present)
2.189 1.239–3.866 0.007 1.736 0.970–3.109 0.063
CEA carcinoembryonic antigen, IAC invasive lung adenocarcinoma, SCC squamous cell lung cancer
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Certain limitations of the current study should be con-
sidered. The study was conducted solely at a single insti-
tution, and the follow-up period was short. A future
multicenter study with a longer follow-up period should
be performed to confirm the current findings. Addition-
ally, due to the relatively small number of cases available,
this study excluded other potentially important histo-
logical NSCLC subtypes (e.g., large cell lung cancer) that
should be included in future investigations. PET scan
was not used in our patients due to availability.
Conclusions
Patients with lung SCC exhibited a significantly higher
rate of lymph node involvement when compared with
IAC patients. Additionally, lymph node involvement was
an independent prognostic factor for pT1 IAC patients.
Thus, our findings suggest that a systematic lymph node
dissection should be conducted in patients with IAC
larger than 1.0 cm.
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